Targovax to Present at NeoAg Summit 2018

OSLO, Nov. 16, 2018 /PRNewswire/ -- Targovax ASA (OSE: TRVX), a clinical stage biotechnology company developing immune activators to target hard-to-treat solid tumors, today announces that CMO Magnus Jäderberg will present at the NeoAg Summit 2018 (formerly Neoantigen Summit) in Boston

NeoAg Summit 2018
Date: 16 November 2018
Presenter: Dr. Magnus Jäderberg, CMO
Presentation time: 11:00 ET
Venue: Hyatt Regency Cambridge, Boston.

Title: TG01, a neo-antigen specific vaccine targeting RAS mutations in solid tumours

Presentation slides will be available on www.targovax.com/Investors.

For further information, please contact:
Renate Birkeli, Investor Relations
Phone: +47-922-61-624
Email: renate.birkeli@targovax.com

Media and IR enquires:
Andreas Tinglum - Corporate Communications (Norway)
Phone: +47-9300-1773
Email: andreas.tinglum@corpcom.no

Simon Conway/Stephanie Cuthbert - FTI Consulting (International)
Phone: +44-20-3727-1000
Email: Targovax@fticonsulting.com

This information was brought to you by Cision http://news.cision.com

http://news.cision.com/targovax/r/targovax-to-present-at-neoag-summit-2018,c2673975

View original content:http://www.prnewswire.com/news-releases/targovax-to-present-at-neoag-summit-2018-300751943.html

SOURCE Targovax